The opioid crisis is one of the deadliest health catastrophes of our time. In the United States alone, more than 80,000 people die each year from overdose — a figure that exceeds total American deaths during the Vietnam War, repeated every year. In Europe, Australia and Canada, similar trajectories are emerging. Legally prescribed medications — OxyContin, Vicodin, fentanyl — have created mass addictions, and thousands of people die each day unable to break the cycle of dependency.
Meanwhile, in laboratories at Johns Hopkins, NYU, Imperial College London and dozens of other universities, researchers are rediscovering something that the 7 Rivers civilization had institutionalized five thousand years ago: certain entheogenic substances, used in a precise ritual framework, can treat addictions that conventional medications cannot reach.
This is not nostalgia. It is pharmacology.
The problem that conventional treatments do not resolve
Current treatments for opioid addiction rely primarily on substitutes — methadone, buprenorphine — that reduce withdrawal symptoms but maintain a dependence on another opioid. They work for many patients. But they do not treat the psychological and existential dimension of addiction.
Addiction is not only a physical dependence. It is also a way of fleeing inner pain — an unresolved trauma, a deep depression, a sense of existential emptiness, an inability to connect with others and with oneself. When the inner pain persists, relapse is frequent even after a successful physical detox.
This is precisely where psychedelic therapies show results unmatched in the history of psychiatry.
Psilocybin against alcohol and tobacco addiction
In The Civilization of the 7 Rivers, I document that the soma of the Vedic civilization contained a tryptamine — from the same family as the psilocybin in Psilocybe mushrooms. And the first clinical studies on psilocybin in addictions are stunning.
In 2014, a pilot study at the University of New Mexico led by Matthew Johnson showed that two to three guided psilocybin sessions enabled 80% of heavy smokers to quit completely — a success rate six times higher than the best conventional treatments. Twelve months after treatment, 67% were still abstinent.
For alcohol, the results are similar. A 2022 study published in the Journal of Psychopharmacology — led by Michael Bogenschutz — showed that after two psilocybin sessions, participants reduced their alcohol consumption by 83% over eight months. No existing medication approaches these figures.
And for opioids themselves — the most lethal addiction — ibogaine, an alkaloid from an African shrub (Tabernanthe iboga) with psychedelic properties, shows extraordinary results. Studies conducted in Mexico, New Zealand and Australia — countries where ibogaine is legal or decriminalized — report that 50 to 70% of patients treated with ibogaine drastically reduce or completely stop their opioid consumption after a single session. Patients who had failed all conventional treatments.
Why it works: the mechanism
What distinguishes psychedelic therapies from conventional treatments is their mode of action. Antidepressants and substitution medications act on brain chemistry continuously and progressively. Psychedelics act differently — they induce an intense modified state of consciousness, of limited duration (4 to 6 hours for psilocybin, up to 24 hours for ibogaine), during which profound psychological experiences occur.
Robin Carhart-Harris’s research at Imperial College identifies the principal mechanism: the temporary dissolution of the ego — what researchers call ego dissolution — which allows a reset of the rigid thought patterns that sustain addiction. Addiction creates deep neurological grooves — cognitive and emotional habits that compulsively draw one back toward the substance. Psilocybin seems to “soften” these grooves, creating a window of psychological flexibility during which new patterns can take hold.
Carhart-Harris has measured this effect: brains under psilocybin show a dramatic increase in connectivity between normally separate brain regions — a “hyperconnectivity” that coincides with the mystical experiences and therapeutic insights reported by patients.
Griffiths, at Johns Hopkins, adds a complementary dimension: many patients describe their psychedelic experience as “one of the most significant of their lives” — an experience that changes their fundamental relationship to existence, allowing them to see their addiction with fresh eyes, from the outside, and to find an intrinsic motivation to change.
What the 7 Rivers civilization understood
What is remarkable in this return of contemporary psychedelic medicine is that it rediscovers precisely what the 7 Rivers civilization had institutionalized for fifteen centuries.
In The Civilization of the 7 Rivers, I document it: the soma experience was ritualized, structured, prepared. It took place in a precise communal context, with experienced guides, after days of preparation through fasting and mantra recitation. What Griffiths calls set and setting — inner disposition and framework — was at the heart of the Vedic protocol from the beginning.
And the fact that all “those responsible for society” — leaders, householders, priests — had to undergo this experience at least once a year had a direct consequence on social organization: a regular experience of ego dissolution mechanically prevents the formation of the oversized Egos that produce addictions to power, accumulation and domination.
The opioid crisis is, in a sense, the consequence of soma’s disappearance. When societies lose their ego-regulation practices, substances that produce immediate relief from inner pain — opioids, alcohol, anxiolytics — become the substitutes for what soma offered in a ritualized and therapeutic way.
Contemporary medicine is not reinventing the wheel. It is recovering a knowledge that the 7 Rivers civilization had perfected over millennia — and whose loss may have cost far more than we imagine.
